|
Vieworks develops, manufactures, and sells imaging solutions, primarily X-ray detectors and industrial cameras. The company operates two main business segments: medical imaging solutions and industrial imaging solutions. In the medical segment, it produces static and dynamic X-ray detectors, including flat panel detectors for digital radiography, fluoroscopy, angiography, and dental applications, as well as a high-resolution digital slide scanner for pathology. In the industrial segment, it supplies high-resolution area-scan and line-scan cameras for machine vision applications, such as automatic optical inspection (AOI) for flat panel displays, semiconductors, and PCBs, as well as cameras for golf simulators and industrial CT inspection. Vieworks serves customers globally, including system manufacturers in the Americas, Europe, and Asia, and major electronics and semiconductor manufacturers in Korea, China, and Japan. The company sells medical products directly to OEMs and through distributors, while industrial products are primarily sold via regional distributors and ODM partners. Notable product lines include the VIVIX series for X-ray detectors, the VN and VP series for industrial cameras, and the VISQUE series for in vivo imaging and digital pathology. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage vieworks.com |
| Sector Healthcare | IR page vieworks.com | |
|
Tags
x-ray detectors, industrial cameras, machine vision, digital pathology, flat panel detectors, area-scan cameras, line-scan cameras, medical imaging, automatic optical inspection, in vivo imaging, VIVIX-S, VIVIX-D, VIVIX-V, VIVIX-M, VN Series, VP-152MX2, VQ Series, VTC Series, VISQUE in vivo Art, VISQUE Smart-LF, VISQUE DPS LH210, VXvue, QXR-Series, Slimpac RF, Maxxray, RXDM-0405
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 9.0% |
| ROI | 8.8% |
| ROIC | 7.1% |
| Profit margin | 9.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -6.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 36.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 239.335B | 222.898B | 220.251B | 237.929B | 193.139B | 160.264B | 136.01B | 131.404B | 123.461B | 117.303B | 93.439B | 70.811B | 66.501B |
| Net profit | 21.971B | 21.297B | 14.715B | 26.539B | 33.474B | 22.893B | 24.216B | 20.771B | 19.631B | 26.979B | 15.897B | 10.48B | 9.466B |
| Free cash flow | 8.232B | 7.447B | 10.272B | -14.93B | 10.734B | -16.918B | 10.572B | 18.452B | 16.2B | 16.161B | 16.351B | -8.746B | 3.357B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 25.8B | 23.1B | 22.9B | 22B | 25.2B | 35.1B | 43.5B | 45.5B | 45.6B | 56.6B |
| ↳ YoY growth | +52.1% | -10.2% | -0.9% | -4.0% | +14.6% | +39.2% | +23.9% | +4.5% | +0.2% | +24.3% |
| ↳ 5y CAGR | +18.6% | +15.5% | +8.3% | +6.4% | +13.5% | +14.7% | +15.7% | +17.6% | ||
| Borrowings, current (KRW) | 1.2B | 358M | 403M | 1.7B | 8B | 21B | 50B | 50.9B | 36.3B | 66.8B |
| Borrowings, non-current (KRW) | 300M | 0.00 | 0.00 | — | — | — | — | 250M | 18.1B | 203M |
| Cash and deposits (KRW) | 34.8B | 37.3B | 46.5B | 53.1B | 39.6B | 41.5B | 41B | 40.8B | 28.2B | 29.6B |
| Intangible assets (KRW) | 2.98B | 3.15B | 6.09B | 6.4B | 6.39B | 6.14B | 6.79B | 9.72B | 8.38B | 7.78B |
| Net debt (borrowings + leases - cash) (KRW) | -33.3B | -36.9B | -46.1B | -51.4B | -31.6B | -20.4B | 8.98B | 10.4B | 26.2B | 37.4B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 19.9B | 18.9B | 27.8B | 18.7B | 6.29B | 16.2B | -1.5B | 23.3B | 35.6B | 37.2B |
| Purchases of property, plant and equipment (KRW) | -3.74B | -2.65B | -9.38B | -8.11B | -23.2B | -5.43B | -13.4B | -13B | -28.1B | -29B |
| Purchases of intangible assets (KRW) | -246M | -1.92B | -348M | -1.27B | -495M | -762M | -1.54B | -2.17B | -829M | -446M |
| Dividends paid (cash effect) (KRW) | -999M | -2B | -1.99B | -2.96B | -3.94B | -4.25B | -6.89B | -6.43B | -3.21B | -5.51B |
| Share buybacks (cash effect) (KRW) | -566M | -2.03B | -2.78B | — | -9.07B | -10.9B | — | 0.00 | 0.00 | -4.99B |
| Interest paid (cash effect) (KRW) | -7.88M | — | -51.7M | -57.1M | -23.2M | -343M | -1.03B | -2.31B | -2.35B | -1.18B |
| Income taxes paid (cash effect) (KRW) | -4.18B | -7.24B | -3.55B | -4.6B | -6.93B | -3.88B | -11.2B | -6.88B | -1.87B | -4.81B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | 15.9B | 14.3B | 18.1B | 9.3B | -17.4B | 9.97B | -16.5B | 8.1B | 6.62B | 7.79B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 27.2B | 19.8B | 20.5B | 23.7B | 21.9B | 33B | 28B | 12.9B | 24.4B | 22.1B |
| Comprehensive income to owners (KRW) | 27.3B | 19.9B | 20.5B | 23.6B | 21.9B | 33B | 28.1B | 12.8B | 24.6B | 23.2B |
| Reported | Mar 31, 2017 | Mar 30, 2018 | Mar 29, 2019 | Mar 30, 2020 | Mar 18, 2021 | Mar 20, 2024 | Mar 20, 2024 | Mar 23, 2026 | Mar 23, 2026 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
2026-08-21

Vieworks, a global imaging solution provider, has set a target of capturing more than 8% of the global digital pathology market within five years through slide scanners optimized for AI-based diagnostics.
Speaking at the Digital Pathology AX (AI Transformation) Conference during K-HOSPITAL + HEALTH TECH FAIR 2026 on Aug. 20, the company said it has begun embedding image pre-processing AI in its VISQUE DPS slide scanner and is preparing for commercialization, with plans to expand supply across North America, Europe and Asia.
Slide scanners serve as the data entry point for AI analysis. A focus deviation of only 1 to 2 micrometers during image acquisition can degrade AI model performance by 5 to 10%. Vieworks developed a deep learning-based scan area detection AI that identifies non-tissue regions such as pen markings, dust and air bubbles at the pixel level, filtering out areas that cause focus errors.
The company reported 99% focus alignment and a focus error rate below 1% in non-tissue regions, reducing re-scans. Technology also maintains focus reproducibility in cytology specimens, where cell overlap and thickness variation are common.
Vieworks is also developing a predictive maintenance AI that continuously monitors robotic arm slide transport through imaging to anticipate faults, supporting uninterrupted high-volume processing in unattended operation.

The presentation also covered Realtime Extended Focus, which acquires three images at different focal planes using three cameras simultaneously and fuses them in real time into a single fully focused image. Vieworks has filed or registered more than 20 patents related to the technology in Korea, the United States, Europe and Japan.
Deployment cases presented included Pennsylvania Dermatology Group in the United States, Ankara Bilkent City Hospital in Türkiye, and several hospitals in Korea.
The company plans to expand its lineup with a compact fluorescence scanner for space-constrained environments and a multi-channel fluorescence scanner for research applications such as spatial biology.
"As AI use expands in pathology, scanners are expected to go beyond image acquisition and produce precise, standardized data that AI can rely on." said Kang Yu-jung, head of the Bio Business Group at Vieworks.
--------------
Vieworks' Digital Pathology System Information
-
Previous
-
List

-
Company
-
Business
-
Investors
-
News
2026-08-04

Vieworks, a leading provider of medical and industrial solutions, reported preliminary consolidated results for the first half of 2026, with revenue of 122 billion won and operating profit of 19.5 billion won, up 4.2% and 127.4% respectively from a year earlier.
"Global expansion in semiconductor inspection equipment investment was reflected in our machine vision results," a Vieworks spokesperson said.
Medical imaging solutions generated about 91.8 billion won, in line with the prior year. Revenue from dynamic X-ray detectors for dental system customers in Europe recovered from a year earlier.
Industrial imaging solutions, or machine vision cameras, generated about 30.2 billion won, up 24.6%. Demand for cameras used in semiconductor inspection equipment recovered, and sales of customer-specific models centered on TDI line scan cameras expanded. In the second half, the company plans to continue developing products with fiber-optic high-speed interfaces.
In new businesses, the digital pathology slide scanner has moved from supply agreements with customers in the United States and Europe to a Korean pathology society exhibition and demonstrations at major domestic hospitals. The company is reviewing entry into Asian markets.
In the golf segment, covering sensors and launch monitors, Vieworks began full-scale supply of launch monitors to NVisage, a U.S. golf imaging brand, alongside its existing ODM business.
-
Previous
-
List

-
Next
-
Company
-
Business
-
Investors
-
News
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Vieworks
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFEV | 0.00% | 5,069 | $ 104.394K | Nov 12, 2026 |
| DFSE | 0.00% | 625 | $ 12.872K | Nov 12, 2026 |
| DFAE | 0.00% | 5,277 | $ 108.677K | Nov 12, 2026 |
| DFEM | 0.00% | 3,618 | $ 74.511K | Nov 12, 2026 |
| DFAX | 0.00% | 4,125 | $ 84.952K | Nov 12, 2026 |
| DEXC | 0.00% | 20 | $ 411.89 | Nov 12, 2026 |
| AVEM | 0.00% | 968 | $ 20.154K | Nov 16, 2026 |















